In short
Clinical trials are investigating ALN-4324 in overweight to obese healthy volunteers and in overweight to obese patients with type 2 diabetes mellitus (T2DM). These studies aim to evaluate safety and tolerability, along with early signs of how the treatment performs in the body.
Key points
- ALN-4324 is being studied in one authorised Phase 1/2 clinical trial. The trial includes overweight to obese healthy volunteers and overweight to obese patients with type 2 diabetes mellitus. Researchers are mainly looking at safety and tolerability, including adverse events, vital signs, ECGs, and laboratory tests. The study plans to enrol 60 people. It is an interventional study, so participants receive a study treatment and are monitored closely.
Trial overview
One authorised Phase 1/2 study is investigating ALN-4324 in people who are overweight to obese, including healthy volunteers and patients with type 2 diabetes mellitus (T2DM). The study is interventional, which means the research team gives a study treatment and then measures the results.
Who is being studied
The trial title says it includes overweight to obese healthy volunteers and overweight to obese patients with T2DM. This means the study is not limited to one group; it is looking at both people without diabetes and people with diabetes in the same weight range.
The condition listed for the study is type 2 diabetes mellitus. T2DM is a long-term condition in which the body does not use insulin properly, leading to high blood sugar.
What the study is measuring
The main outcome is the frequency of adverse events, also called AEs. Adverse events are unwanted medical events that happen during a study, whether or not they are caused by the treatment.
The study also checks safety through vital signs, ECGs, and clinical laboratory assessments. Vital signs are basic body measurements such as blood pressure and pulse. An ECG is a test that records the heart's electrical activity.
The brief summary says the study aims to evaluate the safety and tolerability of multiple doses of ALN-4324 in patients with T2DM. Tolerability means how well people handle the treatment and whether it causes problems that are difficult to accept.
Study design and treatment groups
The trial compares ALN-4324 given subcutaneously with phosphate buffered saline for subcutaneous administration. Subcutaneous means given under the skin.
The source data does not give detailed participant rules, dose amounts, or the exact schedule of visits. It does show that the study is focused on early safety evaluation rather than late-stage treatment testing.
Trial status and size
The trial status is listed as Authorised. The planned enrolment is 60 people. Enrolment means the number of participants planned for the study.